AI could help doctors spot lung cancer earlier, avoid unnecessary biopsies
NCT ID NCT05968898
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an FDA-approved AI software that analyzes CT scans of lung nodules to estimate cancer risk. 300 adults aged 35-89 with newly found lung nodules will be randomly assigned to have their doctors use the AI tool or not. The goal is to see if the AI helps doctors manage nodules more appropriately—recommending monitoring for benign ones and prompt action for cancerous ones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Optellum Virtual Nodule Clinic (AI software device)
What this could lead to
If successful, this AI tool could help doctors more accurately identify which lung nodules are cancerous, leading to faster treatment for cancer and fewer unnecessary biopsies for benign nodules.
What could go wrong
This is a relatively small, early-stage trial (300 participants) testing a device already FDA-approved. The AI may not improve outcomes in all settings, and its effectiveness depends on how doctors use it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Penn Medicine University City
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
-
Penn Medicine Washington Square
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact
-
Perelman Center for Advanced Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact